Related Experiment Video

Updated: Aug 23, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol

Simone Fulda1, Klaus-Michael Debatin

  • 1University Children's Hospital, Prittwitzstr. 43, D-89075 Ulm, Germany.

Oncogene
|July 27, 2004
PubMed

Insights

Resveratrol sensitizes cancer cells to chemotherapy by inducing cell cycle arrest and depleting survivin. This natural compound enhances anticancer drug efficacy, offering a novel therapeutic strategy for various human cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cancer patient survival is limited by tumor cell resistance to therapy.
  • Resveratrol, a natural compound, shows promise as a cancer chemopreventive agent.
  • Targeting tumor cell resistance is crucial for improving cancer treatment outcomes.

Purpose of the Study:

  • To investigate resveratrol's role in sensitizing cancer cells to anticancer drugs.
  • To elucidate the mechanisms by which resveratrol enhances drug-induced apoptosis.
  • To evaluate the potential of combining resveratrol with cytotoxic drugs for cancer therapy.

Main Methods:

  • Cell cycle analysis and apoptosis assays were performed.
  • Resveratrol pretreatment and its effect on drug-induced apoptosis were studied.
  • Survivin expression levels were analyzed following resveratrol treatment.

Main Results:

  • Resveratrol induced S phase cell cycle arrest, leading to survivin depletion.
  • Resveratrol pretreatment enhanced drug-induced apoptosis, particularly outside the S phase.
  • Survivin downregulation, via resveratrol or antisense oligonucleotides, sensitized cells to apoptosis.
  • These effects were observed across various human tumor cell lines, independent of p53 status.

Conclusions:

  • Resveratrol acts as a potent sensitizer for anticancer drug-induced apoptosis.
  • The combination of resveratrol and cytotoxic drugs represents a novel strategy to enhance anticancer therapy efficacy.
  • This approach holds potential for treating diverse human cancers by overcoming drug resistance.

More Related Videos

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...